Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation.
Inhibition of glycogen synthase kinase (GSK)-3 reduces ischemia/reperfusion injury by mechanisms that involve the mitochondria. The goal of this study was to explore possible molecular targets and mechanistic basis of this cardioprotective effect. In perfused rat hearts, treatment with GSK inhibitors before ischemia significantly improved recovery of function. To assess the effect of GSK inhibitors on mitochondrial function under ischemic conditions, mitochondria were isolated from rat hearts perfused with GSK inhibitors and were treated with uncoupler or cyanide or were made anoxic. GSK inhibition slowed ATP consumption under these conditions, which could be attributable to inhibition of ATP entry into the mitochondria through the voltage-dependent anion channel (VDAC) and/or adenine nucleotide transporter (ANT) or to inhibition of the F(1)F(0)-ATPase. To determine the site of the inhibitory effect on ATP consumption, we measured the conversion of ADP to AMP by adenylate kinase located in the intermembrane space. This assay requires adenine nucleotide transport across the outer but not the inner mitochondrial membrane, and we found that GSK inhibitors slow AMP production similar to their effect on ATP consumption. This suggests that GSK inhibitors are acting on outer mitochondrial membrane transport. In sonicated mitochondria, GSK inhibition had no effect on ATP consumption or AMP production. In intact mitochondria, cyclosporin A had no effect, indicating that ATP consumption is not caused by opening of the mitochondrial permeability transition pore. Because GSK is a kinase, we assessed whether protein phosphorylation might be involved. Therefore, we performed Western blot and 1D/2D gel phosphorylation site analysis using phos-tag staining to indicate proteins that had decreased phosphorylation in hearts treated with GSK inhibitors. Liquid chromatographic-mass spectrometric analysis revealed 1 of these proteins to be VDAC2. Taken together, we found that GSK-mediated signaling modulates transport through the outer membrane of the mitochondria. Both proteomics and adenine nucleotide transport data suggest that GSK regulates VDAC and that VDAC may be an important regulatory site in ischemia/reperfusion injury.
Das
Samarjit
S
Department of Pathology, Johns Hopkins University, Baltimore, MD 21205, USA.
Wong
Renee
R
Rajapakse
Nishadi
N
Murphy
Elizabeth
E
Steenbergen
Charles
C
D000227:Adenine Nucleotides / Q000378:metabolism*; D000244:Adenosine Diphosphate / Q000378:metabolism; D000249:Adenosine Monophosphate / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D000627:Aminophenols / Q000494:pharmacology; D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004734:Energy Metabolism / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000071679:Glycogen Synthase Kinase 3 beta; D007211:Indoles / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D008301:Maleimides / Q000494:pharmacology; D008929:Mitochondria, Heart / Q000187:drug effects* / Q000201:enzymology; D000226:Mitochondrial ADP, ATP Translocases / Q000378:metabolism; D033681:Mitochondrial Membrane Transport Proteins / Q000378:metabolism; D051336:Mitochondrial Membranes / Q000187:drug effects* / Q000378:metabolism; D000083162:Mitochondrial Permeability Transition Pore; D009200:Myocardial Contraction / Q000187:drug effects; D015428:Myocardial Reperfusion Injury / Q000201:enzymology / Q000517:prevention & control; D010766:Phosphorylation; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D006180:Proton-Translocating ATPases / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D016277:Ventricular Function, Left / Q000187:drug effects; D050996:Voltage-Dependent Anion Channel 2 / Q000187:drug effects / Q000378:metabolism; D050994:Voltage-Dependent Anion Channels / Q000187:drug effects* / Q000378:metabolism
C417520:3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; D000227:Adenine Nucleotides; D000627:Aminophenols; D002316:Cardiotonic Agents; D004791:Enzyme Inhibitors; D007211:Indoles; D008301:Maleimides; D033681:Mitochondrial Membrane Transport Proteins; D000083162:Mitochondrial Permeability Transition Pore; D019253:Proto-Oncogene Proteins c-bcl-2; C417521:SB 216763; C494767:Vdac2 protein, rat; D050996:Voltage-Dependent Anion Channel 2; D050994:Voltage-Dependent Anion Channels; D000249:Adenosine Monophosphate; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D000226:Mitochondrial ADP, ATP Translocases; D000071679:Glycogen Synthase Kinase 3 beta; D051057:Proto-Oncogene Proteins c-akt; D038362:Glycogen Synthase Kinase 3; D006180:Proton-Translocating ATPases
J Biol Chem. 2002 Mar 1;277(9):7610-8
11751859
J Biol Chem. 2001 Jun 1;276(22):19414-9
11259441
Cardiovasc Res. 2004 Feb 15;61(3):372-85
14962470
Mol Cell Biochem. 2004 Jan-Feb;256-257(1-2):107-15
14977174
Circ Res. 2004 Apr 16;94(7):960-6
14976126
Circ Res. 2004 Apr 30;94(8):1133-41
15031261
J Clin Invest. 2004 Jun;113(11):1535-49
15173880
FEBS Lett. 2004 Jun 18;568(1-3):167-70
15196941
Circ Res. 2004 Oct 1;95(7):734-41
15345651
Circulation. 1986 Nov;74(5):1124-36
3769170
J Biol Chem. 1987 Oct 15;262(29):14042-8
2820993
J Mol Cell Cardiol. 1991 Dec;23(12):1383-95
1839801
J Biol Chem. 1993 Jan 25;268(3):1835-41
8420959
J Biol Chem. 1994 Dec 23;269(51):32187-93
7798217
Biochem J. 1995 Apr 1;307 ( Pt 1):93-8
7717999
Genomics. 1996 Aug 15;36(1):192-6
8812436
FEBS Lett. 1997 Oct 13;416(1):15-8
9369223
Nature. 1999 Jun 3;399(6735):483-7
10365962
Mol Cell. 2004 Dec 3;16(5):819-30
15574336
Expert Opin Ther Targets. 2005 Jun;9(3):447-56
15948666
Biochim Biophys Acta. 2006 Feb;1762(2):181-90
16307870
Cardiovasc Res. 2006 May 1;70(2):212-21
16448635
Proc Natl Acad Sci U S A. 2006 May 9;103(19):7494-9
16648253
Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H748-55
16565311
Cardiovasc Res. 2006 Sep 1;71(4):715-24
16860295
Circ Res. 2002 Mar 8;90(4):377-9
11884365
Nat Cell Biol. 2007 May;9(5):550-5
17417626
Basic Res Cardiol. 2007 Jul;102(4):341-9
17450314
Heart Fail Rev. 2007 Dec;12(3-4):181-8
17516169
Heart Fail Rev. 2007 Dec;12(3-4):217-34
17541822
Circ Res. 2007 Nov 26;101(11):1164-74
17901358
J Appl Physiol (1985). 2007 Dec;103(6):2129-36
17673563
Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1497-500
18223186
Ann N Y Acad Sci. 2008 Mar;1123:197-212
18375592
Circ Res. 2008 May 9;102(9):1082-90
18356542
Curr Drug Targets. 2006 Nov;7(11):1377-88
17100578
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4666-71
10781072
J Biol Chem. 2001 Jan 19;276(3):1954-60
11044447
J Biol Chem. 2001 Jan 26;276(4):2571-5
11073947